Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by eric_julien
Group name EquipeEJ
Item Type Journal Article
Title Anti-HPA-9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy and report on eight families
Creator Kaplan et al.
Author Cécile Kaplan
Author Leendert Porcelijn
Author Philippe Vanlieferinghen
Author Eric Julien
Author Frederic Bianchi
Author Corinne Martageix
Author Gerald Bertrand
Author Vincent Jallu
Abstract BACKGROUND: Fetal or neonatal alloimmune thrombocytopenia (FMAIT) results from a maternal alloimmunization against fetal platelet (PLT) antigens. In Caucasian persons, HPA-1a is the most frequently implicated antigen. During the past few years, FMAIT has been reported associated with rare or private antigens. STUDY DESIGN AND METHODS: Since the first documented case of FMAIT due to anti-HPA-9bw (Max(a)), no additional cases have been reported. Here a retrospective analysis is presented of the cases referred to our laboratories in recent years. The diagnosis was performed by genotyping and identification of the maternal alloantibody by the monoclonal antibody-specific immobilization of PLT antigens (MAIPA) technique. RESULTS: Parental genotyping showed HPA-9bw (Max(a)) mismatch as the sole antigenic incompatibility in seven of eight families. Because the father was found to be HPA-9bw (Max(a)) heterozygous in all the cases, the infant or fetus was genotyped to ascertain the diagnosis. The maternal alloantibody was identified in the MAIPA technique. These data strongly suggest, however, that recognition of the HPA-9bw (Max(a)) epitope is not uniform. The neonatal thrombocytopenia was severe in most cases with bleeding. The outcome was good in all the cases but one. CONCLUSION: This analysis confirms that anti-HPA-9bw (Max(a)) FMAIT is not uncommon and was found to be approximately 2 percent of our confirmed FMAIT cases. It is a clinically severe syndrome that requires prompt diagnosis, albeit difficult, and maternal PLT transfusion therapy. Laboratory investigation of a suspected FMAIT case should be carried out in a specialist laboratory well-experienced in optimal testing. Appropriate management and antenatal therapy should be considered for successive pregnancies to prevent fetal bleeding.
Publication Transfusion
Volume 45
Issue 11
Pages 1799-1803
Date Nov 2005
Journal Abbr Transfusion
Language eng
DOI 10.1111/j.1537-2995.2005.00606.x
ISSN 0041-1132
Short Title Anti-HPA-9bw (Maxa) fetomaternal alloimmunization, a clinically severe neonatal thrombocytopenia
Library Catalog PubMed
Extra PMID: 16271107
Tags Antigens, Human Platelet, Diagnosis, Differential, Female, Fetal Diseases, Humans, Immunoglobulins, Intravenous, Infant, Newborn, Infant, Newborn, Diseases, Isoantibodies, Maternal-Fetal Exchange, Platelet Count, Platelet Transfusion, Pregnancy, Retrospective Studies, Severity of Illness Index, Thrombocytopenia, Treatment Outcome
Date Added 2018/09/26 - 15:50:01
Date Modified 2018/09/26 - 15:50:01


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés